# About KLOW Meds — Independent editorial publisher of research summaries

> KLOW Meds is an independent editorial project that publishes summaries of peer-reviewed research on the KLOW peptide blend and its four components. Not a clinic, vendor, or pharmacy.

KLOW Meds is an independent publisher that summarizes the peer-reviewed literature on GHK-Cu, BPC-157, TB-500, and KPV. We are not a clinic, pharmacy, or vendor.

## What KLOW Meds is

KLOW Meds is an independent editorial project that publishes summaries of the peer-reviewed research literature on the KLOW peptide blend (GHK-Cu, BPC-157, TB-500, and KPV) and on each of its four components individually. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The 'meds' modifier in the domain name is editorial framing — the position the publisher occupies relative to the literature, not a claim about the site's services. This is a reference library that draws the KLOW research record to scale. It is not a treatment provider, not a vendor, and not a pharmacy.

## Editorial standards

Every quantitative claim on this site cites a peer-reviewed source. The reference index on /references lists 23 citations with DOIs and links to PubMed, PMC, or the original publisher. Where the literature is sparse — most notably for the four-peptide combination, for KPV human trials, and for blend pharmacokinetics — we say so explicitly and document the gap rather than smooth over it.

We write in a technical-trust register adapted for the blueprint format: each peptide is rendered as its own annotated subassembly, mass ratios are drawn to scale, and the absence of a combination trial is documented as a literal empty cell rather than papered over. Where vendors and hobbyist sources extrapolate from monotherapy data to combination claims, we mark the extrapolation and decline to repeat it. Where a result comes primarily from one research group (notably, much of the BPC-157 mechanistic literature concentrates in the Sikiric group at the University of Zagreb), we note that the result has not been independently replicated across multiple centers.

## What KLOW Meds is not

We do not sell peptides. We do not ship peptides. We do not run a compounding pharmacy. We do not provide consultations, prescriptions, telehealth visits, lab orders, dosing schedules, or any other clinical service. We are not affiliated with any peptide vendor, supplier, or pharmacy. None of the writing on this site is medical advice.

If a reader has questions about peptide research for a regulated clinical context, those questions belong with a licensed clinician, IRB, or regulatory authority — not with an editorial publisher.

## Methodology

The site is sourced from PubMed-indexed primary research, systematic reviews, narrative reviews, FDA guidance documents, and the WADA Prohibited List. Two 2025 reviews on the reference list are preprints and are flagged as such inline. No source on the list is a vendor product page, hobbyist forum, or non-peer-reviewed blog.

We revise pages when new data emerges — for example, the BPC-157 FDA Category 2 status and the April 2026 removal from Category 2 are documented as a tracked timeline rather than a single snapshot. KPV's mid-2026 FDA Pharmacy Compounding Advisory Committee review is similarly tracked. When trial results are published that change the record, we update the affected pages and mark the revision date in the title block.

---

A technical reference set for the peer-reviewed literature — not a clinic, not a vendor, not a prescription.